Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm

Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm

Patrocinadores

Patrocinador principal: Centre Hospitalier Universitaire, Amiens

Fuente Centre Hospitalier Universitaire, Amiens
Resumen breve

Action slowing has been demonstrated in many diseases. Parkinson's disease (PD) and Huntington's disease (HD) are two neurodegenerative diseases affecting the basal ganglia, particularly the medial globus pallidus, and the clinical expression of these two diseases is characterized by a combination of motor and cognitive disorders, but with two opposing patterns of dysfunction. Action slowing has been demonstrated in both of these diseases and has been extensively studied in Parkinson's disease, suggesting a perceptive-cognitive origin. Far fewer studies have been conducted in Huntington's disease. However, all of these studies were performed with different methodologies in small cohorts and the value of the proposed study is to use a validated and standardized computerized mental chronometry paradigm, providing a better understanding of the mechanisms of action slowing in these two diseases and to more clearly define a disease-specific profile.

Estado general Completed
Fecha de inicio July 2011
Fecha de Terminación November 2016
Fecha de finalización primaria November 2016
Tipo de estudio Observational
Resultado primario
Medida Periodo de tiempo
SRT Day 0
Inscripción 55
Condición
Intervención

Tipo de intervención: Behavioral

Nombre de intervención: SRT

Descripción: simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

Elegibilidad

Método de muestreo: Non-Probability Sample

Criterios:

Inclusion Criteria:

- Agreeing to participate in the study

- French mother tongue

- MMSE > 20/30

- Specific to the MP and MH:

- Parkinson's disease:

- defined by the criteria of the UKPDSBB

- stage 1 , 2 or 3 Hoehn and Yahr (ON)

- age of onset of the disease known

- brain MRI performed during follow-up

- Huntington disease :

- genetically defined (CAG > 35)

- weaning neuroleptic ( Tercian® and Solian® : 2 days; Haldol® : 5 days ; Tiapridal® and Xenazine : 1 day ; Zyprexa® : 4 days)

- Early stage : Fahn and Shoulson I and II is a CFT score between 7 and 13

Exclusion Criteria:

- Illiteracy, writing or reading difficulties

- Visual perceptual auditory deficit or preventing reading, drawing, writing or understanding instructions

- Visual hallucinations

- Significant history may sound on cognition (unbalanced thyroid dysfunction, ischemic heart disease or embolic unstabilized or symptomatic, progressive neoplasia, chronic alcoholism weaned or not)

- Current or previous neurological diseases other than MH or MP: ischemic cerebral vascular accident or bleeding, head injuries (loss of higher knowledge in 15 minutes), epilepsy requiring treatment.

- Psychiatric disorders depression unless treated (stable treatment for 1 month)

- Psychotropic treatment (except anxiolytic, antidepressant steady since 1 month)

- Inability to achieve an autonomous operation without technical assistance over a distance of 20 meters.

- Inability to stand without technical assistance for 30 seconds.

Género: All

Edad mínima: 18 Years

Edad máxima: N/A

Voluntarios Saludables: No

Oficial general
Apellido Papel Afiliación
Pierre KRYSTKOWIAK, MD, PhD Principal Investigator CHU Amiens
Ubicación
Instalaciones: CHU Amiens
Ubicacion Paises

France

Fecha de verificación

December 2016

Fiesta responsable

Tipo: Sponsor

Palabras clave
Tiene acceso ampliado No
Condición Examinar
Grupo de brazo

Etiqueta: Parkinson best-On

Descripción: two hours after taking two tablets of 125 mg dispersible Modopar®

Etiqueta: Parkinson worst-off

Descripción: after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)

Etiqueta: Huntington

Etiqueta: Control

Descripción: Data collected from the existing database

Acrónimo ERAMPPCI
Información de diseño del estudio

Modelo de observación: Case Control

Perspectiva de tiempo: Prospective

Fuente: ClinicalTrials.gov